Stockscreener 앱 받기
16.25
2.63%
0.42
전일 마감가:
$15.83
열려 있는:
$15.825
하루 거래량:
849.28K
Relative Volume:
0.84
시가총액:
$1.21B
수익:
$17.49M
순이익/손실:
$-78.50M
주가수익비율:
-13.54
EPS:
-1.2
순현금흐름:
$-52.85M
1주 성능:
+14.17%
1개월 성능:
+25.94%
6개월 성능:
+55.77%
1년 성능:
+27.02%
1일 변동 폭
$15.72
$16.31
1주일 범위
$12.86
$16.31
52주 변동 폭
$8.26
$16.81
Liquidia Corp Stock (LQDA) Company Profile
명칭
Liquidia Corp
전화
919.328.4400
주소
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
LQDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
16.25 | 1.21B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.59 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.91 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.33 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.92 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.00 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-16 | 개시 | Raymond James | Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Perform |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2022-09-19 | 재개 | Wedbush | Underperform |
| 2022-09-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2022-07-22 | 개시 | Ladenburg Thalmann | Buy |
| 2022-05-31 | 개시 | BTIG Research | Buy |
| 2022-05-26 | 개시 | BofA Securities | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-05 | 개시 | Wedbush | Outperform |
| 2018-08-20 | 개시 | Jefferies | Buy |
| 2018-08-20 | 개시 | Needham | Buy |
모두보기
Liquidia Corp 주식(LQDA)의 최신 뉴스
UTC can't counterclaim over amended Liquidia drug application, US judge says - MLex
Liquidia (LQDA) Receives Price Target Upgrade from Scotiabank | LQDA Stock News - GuruFocus
Liquidia (LQDA): Scotiabank Raises Price Target and Maintains Outperform Rating | LQDA Stock News - GuruFocus
Scotiabank raises Liquidia stock price target to $36 By Investing.com - Investing.com India
Scotiabank raises Liquidia stock price target to $36 - Investing.com
Legal Victory for Liquidia Corporation (LQDA) in YUTREPIA Inhalation Powder Case | LQDA Stock News - GuruFocus
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - The Manila Times
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - GlobeNewswire Inc.
Liquidia Technologies stock surges on legal win By Investing.com - Investing.com South Africa
Liquidia Technologies stock surges on legal win - Investing.com Australia
Liquidia (LQDA) Clears Legal Hurdle, Prepares for Yutrepia Launch | LQDA Stock News - GuruFocus
Liquidia (LQDA) Jumps 15% as Court Clears Path for Yutrepia Launch - GuruFocus
Liquidia (LQDA) Price Target Increased Following Legal Victory | LQDA Stock News - GuruFocus
UTC Bid to Delay Liquidia’s Yutrepia Launch Shot Down by Judge - Bloomberg Law News
Liquidia surges 15% as court clears way for Yutrepia launch (updated) - Seeking Alpha
Deeper Dive: Understanding Liquidia Corp (LQDA) Through its Various Ratios - DWinneX
Did Liquidia Corp (LQDA) perform well in the last session? - uspostnews.com
Does Liquidia Corp (LQDA) offer a good opportunity for investors? - Sete News
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
LQDA: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Liquidia Corp [LQDA] Stock sold by Insider Saggar Rajeev for $33492.0 - knoxdaily.com
Liquidia Corp's chief medical officer sells $31,785 in stock - MSN
Was anything positive for Liquidia Corp (LQDA) stock last session? - uspostnews.com
Liquidia Corp files patent infringement suit against United Therapeutics By Investing.com - Investing.com Canada
Liquidia Corp files patent infringement suit against United Therapeutics - Investing.com
Liquidia Sues UTC Seeking Patent Damages for Tyvaso DPI Drug (1) - Bloomberg Law News
Liquidia Corp’s chief medical officer sells $50,398 in stock By Investing.com - Investing.com Canada
Liquidia Corp Executives Sell Shares Under Rule 10b5-1 Plan - TradingView
Liquidia Corp’s chief medical officer sells $50,398 in stock - Investing.com
Liquidia Corp’s chief business officer Jason Adair sells shares worth $25,185 - Investing.com India
Great week for Liquidia Corporation (NASDAQ:LQDA) institutional investors after losing 1.5% over the previous year - Yahoo Finance
Breaking Down Liquidia: 4 Analysts Share Their Views - Benzinga
Liquidia at Needham Conference: Strategic Insights on Eutropia Launch - Investing.com Australia
Liquidia at Needham Conference: Strategic Insights on Eutropia Launch By Investing.com - Investing.com India
Liquidia: United Therapeutics Has The Last Laugh (LQDA) - Seeking Alpha
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Liquidia (NASDAQ:LQDA) - Defense World
Liquidia Corp (LQDA) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
UPDATELiquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - Yahoo Finance
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Liquidia Technologies (LQDA) Receives a Buy from Scotiabank - The Globe and Mail
Liquidia Co. (NASDAQ:LQDA) Receives $26.63 Average Price Target from Analysts - The AM Reporter
Liquidia says its request for Yutrepia final approval undergoes FDA review - MSN
Liquidia stock rises as Yutrepia undergoes FDA review (LQDA) - Seeking Alpha
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder - Investing.com
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA - TipRanks
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder By Investing.com - Investing.com Canada
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder - The Manila Times
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
What is Lifesci Capital’s Estimate for Liquidia Q2 Earnings? - The AM Reporter
Liquidia Corporation (NASDAQ:LQDA) Q4 2024 Earnings Call Transcript - Insider Monkey
Liquidia Corp (LQDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Liquidia Corp 주식 (LQDA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Saggar Rajeev | Chief Medical Officer |
Apr 21 '25 |
Sale |
13.67 |
2,450 |
33,492 |
263,152 |
| Schundler Russell | General Counsel |
Apr 14 '25 |
Sale |
13.57 |
5,964 |
80,931 |
570,301 |
| JEFFS ROGER | Chief Executive Officer |
Apr 14 '25 |
Sale |
13.57 |
14,130 |
191,744 |
1,006,420 |
| Moomaw Scott | Chief Commercial Officer |
Apr 15 '25 |
Sale |
13.57 |
3,406 |
46,219 |
214,744 |
| Kaseta Michael | CFO and COO |
Apr 14 '25 |
Sale |
13.57 |
8,283 |
112,400 |
396,315 |
| Saggar Rajeev | Chief Medical Officer |
Apr 14 '25 |
Sale |
13.57 |
3,714 |
50,399 |
265,602 |
| Adair Jason | Chief Business Officer |
Apr 14 '25 |
Sale |
13.57 |
1,856 |
25,186 |
184,304 |
| Schundler Russell | General Counsel |
Mar 03 '25 |
Sale |
15.45 |
930 |
14,368 |
576,265 |
| Moomaw Scott | Chief Commercial Officer |
Mar 03 '25 |
Sale |
15.45 |
592 |
9,146 |
218,150 |
| Kaseta Michael | CFO and COO |
Mar 03 '25 |
Sale |
15.45 |
874 |
13,503 |
404,598 |
0.27%
0.30%
자본화:
|
볼륨(24시간):